latest news at shaare zedek

A New Generation

10 July 2018

New medical breakthroughs are increasingly demonstrating that the genes we inherit from our parents play a crucial role in our future health.

Each of us has a unique DNA profile which includes our personal medical characteristics.  Doctors are recognising that our DNA is the key to personalised targeted prevention and treatment of an increasing number of diseases.

And we know that there are certain genes that are more common in people of Jewish heritage.

Shaare Zedek Medical Centre has a profound understanding of specific genetic challenges facing the Jewish community worldwide.

As Jerusalem’s most central major hospital, treating over 750,000 patients per annum, and a strong commitment to medical research, innovation and ethics, Shaare Zedek is uniquely positioned with a rich knowledge base that has serious implications for each one of us individually.

Shaare Zedek’s medical breakthroughs directly affect your health.

It was Shaare Zedek’s Medical Genetics Unit that identified the high rate of BRCA 1 and 2 mutations in people of Jewish heritage, and the connection to an increased risk of breast and ovarian cancer. Studies are now in place to determine how this applies to the Australian Jewish Community.

The Australian Friends of Shaare Zedek Inc works hand in hand with the hospital in Jerusalem to facilitate studies, share information and help our local community prevent and treat genetic conditions that are all too familiar to us.

This year, AFSZ Inc is set to launch its annual Shabbat Nachamu appeal to raise funds for a new generation genetic sequencer at the hospital in Jerusalem.

The new generation sequencer will enhance Shaare Zedek’s ability to identify and treat genetic diseases.  It will enable geneticists to analyse millions of molecules and target the causes and manifestations of genetic disease.

From IVF to cancer diagnosis and treatment and through to geriatrics, the sequencer at Shaare Zedek will enable doctors to initiate risk reduction interventions and to personalise treatments.

The results?

  • Healthy babies free of genetic disease even when both parents are carriers.
  • Cancer treatment that is targeted and with a far higher success rate.
  • Patients with a personalised analysis of their disease and with the best treatment and preventative plan tailored to their individual genetic profile.
  • A greater and more profound understanding of genetic diseases to which the Jewish community worldwide is predisposed.

Dr Allan Garfield, Chairman of the AFSZ Inc says, “We ask the Australian community to please donate generously to this year’s Shabbat Nachamu Appeal.

“This year, your tax-deductible donation to AFSZ Inc is a true investment in your personal health, our local community’s health, and the health of Jerusalem’s most crucial medical institution.”